Pharmaceutical Industry Articles & Reports

Compare top 2026 pharma real-world data (RWD) platforms like IQVIA, Komodo, and Truveta. Review pricing models, analytic features, and use-case applications.

Analyze Cohere's acquisition of Reliant AI and the North for Pharma launch. Understand how agentic AI and biomedical research workbenches impact drug R&D.

A complete guide to pharmaceutical Computer System Validation (CSV) services. Reviews GxP RFP templates, vendor scorecards, and 2026 pricing benchmarks.

Review the May 2026 FDA approval of Baxfendy (baxdrostat), analyzing its mechanism as an aldosterone synthase inhibitor for uncontrolled hypertension.

Analyze AstraZeneca's acquisition of Modella AI. Learn how multimodal foundation models integrate into oncology drug discovery and impact pharma AI M&A trends.

Analyze the FDA approval of Immgolis (golimumab-sldi), the first interchangeable Simponi biosimilar. Learn how auto-substitution impacts rheumatology care.

Explore the May 2026 FDA leadership shakeup, including Marty Makary's resignation. Learn how new acting directors impact drug approvals and FDA AI policy.

Analyze the rise of direct-to-patient pharma platforms. Learn how DTP models integrate telehealth, bypass PBMs, and disrupt traditional pharmacy supply chains.

Analyze Eli Lilly's 2026 AI partnership map and co-innovation strategy. Learn how collaborations with NVIDIA, Insilico, and Chai advance drug discovery.

Review 2026 GLP-1 market access metrics, including PBM prior authorization denial rates, turnaround times, and first-fill benchmarks for commercial teams.

Examine the FDA accelerated approval of Beqalzi (sonrotoclax), the first BCL-2 inhibitor for relapsed mantle cell lymphoma, including efficacy and safety data.

Learn about the mechanics of in vivo CAR therapies using mRNA-LNP technology and explore the growing landscape of AI-driven drug discovery in biotechnology.

Comprehensive guide to GxP environmental monitoring systems (EMS) for small biotech. Review FDA 21 CFR Part 11, EU GMP Annex 1, and vendor selection criteria.

Review Kanvas Biosciences' AI live biotherapeutics for refractory oncology. Explore how spatial microbiome mapping and KAN-001 impact cancer immunotherapy.

An in-depth analysis of Isomorphic Labs' $2.1B Series B funding. Examine the IsoDDE AI drug design engine, AlphaFold's role, and biotech industry impacts.

Learn how AI predictive tools and animal-free testing methods (NAMs) are advancing drug discovery. Read this technical review of AAPS NBC 2026 innovations.

An analysis of the May 2026 FDA label expansion for Vyvgart (efgartigimod) in generalized myasthenia gravis, covering triple seronegative subtypes and markets.

Analyze the May 2026 FDA drug repurposing initiative. Learn how AI indication discovery and real-world evidence shape regulatory pathways like 505(b)(2).

Examine BioNTech's 2026 restructuring toward oncology amid declining COVID-19 vaccine revenues, and explore post-pandemic Big Pharma pipeline strategies.

Examine Merck's 2026 restructuring and 8% workforce reduction. Understand how the company utilizes AI and M&A to navigate the $300B pharma patent cliff.

Compare leading AI HCP engagement platforms for pharma commercial operations. Review the 2026 capabilities of Aktana, OptimizeRx, Pega, and Veeva Vault CRM.

Analyze Takeda's 2026 restructuring plan, including 634 US job cuts and $1.26B in savings. Learn how the patent cliff is driving a pharma operating-model reset.

Analyze Pfizer's $10B acquisition of Metsera and the evolving GLP-1 obesity drug market. Learn about competing pipelines, clinical data, and pharma strategy.

Analyze the 2026 FDA Accelerated AI Pathway Pilot. Review the regulatory framework and the 10 selected companies advancing AI-discovered drugs to Phase I.